About PATHWAYS
Health pilot projects support Indigenous communities burdened with high rates of chronic diseases.
PATHWAYS is a collaboration between Boehringer Ingelheim (Canada) Ltd., Bimaadzwin and Indigenous health policy leaders from across Canada. Funding is available to advance national health and wellness projects that go “beyond the pill” in addressing type 2 diabetes and/or chronic obstructive pulmonary disease among Indigenous Peoples in Canada. Further investments in other chronic illnesses, such as interstitial lung disease, are planned following the successful launch of four initial pilot projects in 2021.
It started in 2018 when Chief Isadore Day and I met while he was still the Health Minister for the Assembly of First Nations. And we began talking about Boehringer Ingelheim, our approach to serving humankind.
Pulmonary disease.
We wanted to have the Indigenous community inform Boehringer Ingelheim in our collaborations with Indigenous communities, and we found a common purpose. And, that's how we started down this journey.
We were approached by Boehringer Ingelheim Canada to run this virtual diabetes care pilot project. And so we applied for a small grant and were successful. And so far we've been using the funds to help facilitate travel to these more remote communities and also, to purchase A1C testing devices, including the A1CNow and DCA Analyzer cassettes. Ideally, what we'd also be doing is training more case managers to help facilitate these consultations with a virtual endocrinologist because there is such a big distance in between all the Nuu-chah-nulth Nations.
An ethical partnership is where you listen to the Indigenous community as to what their needs are. You respect the community to know what is best for their community in optimizing care.
About Bimaadzwin
An Indigenous-led consulting and policy group founded by former Ontario Regional Chief Isadore Day, Bimaadzwin’s focus is enabling First Nations communities to successfully reconstitute Nationhood by advancing health governance and economic development.
About Boehringer Ingelheim (Canada) Ltd.
Through our participation in medical and pharmaceutical research, both in Canada and worldwide, we have contributed to significant improvements in healthcare and developed innovative and cost effective medicines. We have earned a reputation as a leader in the treatment of respiratory diseases, in particular Chronic Obstructive Pulmonary Disease (COPD), and have broadened the scope of our work to include diseases such as hypertension, stroke, arthritis, benign prostatic hyperplasia (BPH), Parkinson's disease and HIV/AIDS.
We are constantly seeking new and better ways to treat people and animals. In the space of just two years, we have introduced several new products and have a number of new compounds in the pipeline. We have participated in joint ventures with other top multinational pharmaceutical companies - ventures that have improved quality of life for many thousands of Canadians and have perhaps saved the lives of thousands more.
While our German parent company stands among the world’s 20 largest human pharmaceutical research and development businesses, it has remained a family held company for over a century. As our ownership has remained unchanged, so have our guiding principles. Since our founding, we have practiced excellence, innovation and value in the discovery of medicines and services, and we have always acted in the firm knowledge that people and service are our priorities
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
The Canadian headquarters of Boehringer Ingelheim (Canada) Ltd. was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario.
For more information about Boehringer Ingelheim (Canada) Ltd. Visit the site.
